Clinical trial · Interventional
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients
NCT06824818CI-TRIAL-00096062recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Elderly | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LHRH Agonist Therapy Discontinuation | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- discontinuation of LHRH agonist therapy in elderly prostate cancer patients
- interventionNames
- Behavioral: LHRH Agonist Therapy Discontinuation
Primary outcomes (1)
- measure
- feasibility of stopping LHRH agonist therapy
- timeFrame
- 12 months after discontinuing LHRH agonist therapy
- description
- Fraction of patients maintaining castrate testosterone levels
Secondary outcomes (6)
- measure
- Patient interest in stopping treatment
- timeFrame
- End of enrollment (approximately 3 years after study start)
- description
- Percentage of patients that decline participation in the study
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Prostate cancer with \>3 years of LHRH agonist therapy. * Age ≥70 years. * ECOG performance status ≤2 * Baseline testosterone of \< 20 ng/ml * No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable). * Ability to understand and sign informed consent. Exclusion Criteria: * none
References
Publications (0)
Data not yet available
No reference posted for this study.